Fanvue | $22,000,000 | (Jan 20, 2026)
Dominion Dynamics | $15,200,000 | (Jan 20, 2026)
Tulip Interfaces | $120,000,000 | (Jan 20, 2026)
Generare
France
- Paris, Île-de-France
- 08/10/2024
- Seed
- $5,495,250
Natural products have contributed more than 500 molecules to pharmaceuticals.
However, conventional methods for discovering new natural products are increasingly ineffective.
Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution.
This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation.
- Industry Biotechnology Research
- Website https://generare.bio/
- LinkedIn https://www.linkedin.com/company/generare-bioscience/
Related People
Guillaume VandeneschFounder
France -
Paris, Île-de-France
Biotech Engineer with 10+ years exp in innovation & and consulting.
- Successful exit Possible Future 2022 to Capgemini Invent
Launched Generare in March 23' to revolutionize early drug discovery
Generare is a data-driven discovery platform that will revive the field of natural products, bringing this historically successful modality into the clinical pipelines.
Our POC in Nat Coms by Dr. Vincent Libis : http://bit.ly/3RL6JPL
Underlying tech awarded with ERC Starting Grant
More info about Generare available at https://docsend.com/view/dvwzjcj6n4vx36y9
Fleetzero | $43,000,000 | (Jan 20, 2026)
EXCIVA GmbH | $59,817,135 | (Jan 20, 2026)
Transition Metal Solutions | $6,000,000 | (Jan 20, 2026)
one • fıve | $16,320,500 | (Jan 20, 2026)
Anzen Industries | $2,283,975 | (Jan 20, 2026)
Gutology | $2,418,300 | (Jan 20, 2026)
GovDash | $30,000,000 | (Jan 16, 2026)
RouteSense | $2,000,000 | (Jan 16, 2026)
Vista AI | $29,500,000 | (Jan 16, 2026)